IFRX-Small-Talk WKN: A2H7A5 ISIN: NL0012661870 Kürzel: IFRX Forum: Aktien User: gustl2019

Naja das schöne bei solchen Werten ist ja das es ganz schnell gehen kann. Und da sind ein paar hundert Prozent schnell erreicht. Leider für beide Richtungen.

Nur 8? Ich erwarte schon, dass das GAP vom 28. Mai 2019 geschlossen wird.

Bin erst wieder zufrieden wenn ich hier die 8 € pro Aktie im Depot sehe 😉

Schade, leider Non Event. News klingt eigentlich nicht so schlecht, aber war ja auch irgendwie klar dass nicht viel nach oben passiert.

Dip´s gabs doch genug...ich brauche keine mehr ;-)

ich würde hier gerne weiter aufstocken. Mal schauen wann es wieder einen ordentlichen Dip gibt. Wenn nicht wäre das natürlich auch völlig ok ;)

Dann haben wir ja wenigstens den Übeltäter:-) Aber jetzt steigt es ja.

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 • SAD data confirm best-in-class potential for INF904 as orally administered C5aR inhibitor: o Safety and tolerability with no signals of concern over entire dose range o Pharmacokinetics (PK): favorable dose-proportional systemic exposure with overall PK profile confirming pre-clinical data o Desired blocking activity (>90%) of C5a-induced neutrophil activation at disease relevant C5a levels 24 hours post administration for doses of 30 mg to 240 mg o INF904 can be formulated with drug strength of 30 mg per capsule • Data from the ongoing multiple ascending dose (MAD) part of the study to be presented in early 2024 • Company to host a conference call today, September 11, 2023 at 8:30 am EDT/14:30 CEST Jena, Germany, September 11, 2023 – InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today its topline results from the single ascending dose (SAD) part of its randomized, double-blind, placebo-controlled Phase I trial of the orally administered, low molecular weight C5aR inhibitor INF904. In the SAD part of the study, INF904 demonstrated an excellent safety and tolerability profile as well as a very favorable pharmacokinetic (PK) and pharmacodynamic (PD) profile, confirming INF904 ́s best-in-class potential. The SAD part of the Phase I first-in-human trial enrolled 62 healthy volunteers within six different dosing groups from 3 mg to 240 mg who were randomly assigned to receive INF904 or a placebo. Different drug concentrations were tested for the 60 mg dosing group. The main objectives were to assess safety and tolerability of single ascending doses under fasting conditions. Secondary endpoints included several PK parameters, and the effect of INF904 on C5a-induced neutrophil activation in blood samples from treated volunteers ex vivo also was explored. “Our team has spent several years developing an orally administered inhibitor of the terminal complement C5a / C5aR pathway with optimized PD and PK properties primarily for the long- term treatment of patients with chronic inflammatory conditions in need of improved therapeutic options. We are very pleased that the results announced today confirm our pre-clinical studies with INF904, which did not reveal any safety concerns and demonstrated favorable PK and PD